Participated in TRIANA Biomedicines' oversubscribed $120M Series B financing to advance its molecular glue degrader pipeline.
TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel therapeutics to treat diseases
TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel therapeutics to treat diseases. The company focuses on molecular glues that promote protein interactions to alter the fate or function of disease target proteins, particularly in cancer treatment.